Acclarent’s Balloon Sinuplasty Device Relieva Heads To Asian Clinics
This article was originally published in PharmAsia News
Executive Summary
Johnson & Johnson subsidiary Acclarent demonstrated its hand-held Relieva sinuplasty technology with its first in-office demonstration procedure in Malaysia, seeking to highlight the minimally invasive procedure for sinusitis as the company starts a push in Asia.
You may also be interested in...
Companies See Opportunities In Expanding ENT Market
The ear, nose, and throat market now boasts several large device manufacturers that see possibilities in this space for innovative new minimally invasive products. Such competition is the ideal landscape for innovation, as the large companies battle for market share, while start-up firms and VCs see opportunities to take the market in new directions.
Intersect Follows Leaders In ENT
Following the lead of ENT start-ups like Acclarent and Entellus Medical, Intersect ENT Inc. is introducing a line of stent like implants capable of performing the same role drug-eluting stents played in interventional cardiology. Intersect’s implants provide moderate structural support to tissue that has been cut or dilated through FESS or balloon sinuplasty. But the principal function of the implant isn’t propping open nasal passageways but rather delivering drugs. A trio of clinical studies conducted by the company has found the released steroids produced statistically significant reductions in inflammation, polyp formation, and postoperative adhesions.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.